Social implication, economic aspects and new abilities of strontium ranelate in pharmacotherapy for postmenopausal osteoporosis

Abstract

The authors have analyzed the efficiency of and clinicoeconomic prospects for the use of strontium ranelate, by taking account epidemiological data and management costs for postmenopausal osteoporosis (OP). Strontium ranelate both stimulates the formulation of bone tissue and suppresses its resorption, by generating a new bone tissue and ensuring early and long-term prevention of fractures. It is noted that strontium ranelate is now the only drug for the treatment of OP, by physiologically affecting bone metabolism. Furthermore, it is an agent with proved efficacy in OP patients over 80 years of age. The authors show that it is clinically and economically expedient to use strontium